SLGL Sol-Gel Technologies, Ltd.: Koefisien utang jangka dawa marang modal

The development of innovative silica microcapsules by Sol-Gel Technologies (SLGL) relies on Israeli laboratories and production outsourcing in the US. The current long-term debt-to-equity trend captures this growth, where 0.01 records a new level. Simultaneously, Sol-Gel Technologies (SLGL) is implementing energy-efficient equipment and safe waste disposal, adhering to strict ESG environmental standards in pharmaceuticals.

The stable cash flow from dermatological drug licenses at Sol-Gel Technologies (SLGL) aligns with the current long-term debt-to-equity dynamics. This ratio compares liabilities with a maturity of over one year against the business's own equity. The metric determines the company's degree of dependence on external financing and its resilience to rising interest rates. Low leverage, combined with maintained operational momentum, minimizes default risks. Investors should evaluate the balance between financial leverage and the capital base.